Bajaj Finance reported a 17% growth in consolidated net profit for the third quarter of FY25 at ₹4,247 crore as against ₹3,639 crore in the year ago period.
Bajaj Healthcare has received approval from India's Drug Controller General to manufacture Pimavanserin, a drug for Parkinson's-related hallucinations and delusions. Pimavanserin, already popular in ...